Yaz Dangers Withheld from FDA & Consumers
Recent studies have shown that women using Yaz and Yasmin birth control pills have a higher risk of experiencing a blood clot while on the pills, but new findings show Bayer knew about the risk as early as 2004.
Former FDA commissioner David Kessler testified in an Illinois federal court that Bayer omitted from its safety analysis of Yaz/Yasmin reports of an increased risk of venous thromboembolism, which can lead to a potentially deadly pulmonary embolism.
By omitting this data, Kessler testified that “Bayer presented a selective view of the data, and that the presentation obscured the potential risks associated with Yasmin.”
Venous Thromboembolisms
One of the most significant risks associated with Yaz/Yasmin is that of a venous thromboembolism, or a blood clot. Blood clots can be deadly if they lead to deep venous thrombosis (DVT) or a pulmonary embolism.
DVT mainly occurs in the lower extremities, but can occur in the upper extremities as well. Symptoms of DVT include swelling, pain, tenderness, and skin that is warm to the touch.
Pulmonary embolisms occur after a blood clot has been released into the bloodstream. If the blot gets stuck in the heart, brain, or other major organs, severe damage or even death may occur.
Yaz & Yasmin Lawsuits
More than 10,000 lawsuits have been filed against Bayer, alleging women taking the pills suffered injuries. At least 50 women died from taking Yaz and Yasmin between 2004 and 2008.
Yaz and Yasmin are two of the top oral contraceptives on the U.S. market, generating $1.58 billion in sales last year alone.
If you or a loved one has experienced a blood clot, DVT, or pulmonary embolism while taking Yaz, Yasmin, or another birth control containing the synthetic hormone Drospirenone, experienced dangerous drug attorney Kay Van Wey may be able to help you. Call Van Wey Law today at (800) 498-5082 for more information.
